ASH 2017 | Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies

Susan O’Brien

In this interview, Susan O’Brien, MD, of the University of California, Irvine, CA, talks to us about the next-generation PI3Kδ inhibitor umbralisib for patients with relapsed/refractory lymphoid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Prof. O’Brien discusses the large-scale safety data presented. She highlights the importance of this data, and compares umbralisib to idelalisib and duvelisib.

Share this video